These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 37859677)
1. A Comparative Study of Hemorrhagic Conversion Patterns After Stroke Thrombolysis With Alteplase Versus Tenecteplase. Ezzeldin M; Hill C; Kerro A; Percenti E; Delora A; Santos J; Saei H; Greco L; Ezzeldin R; El-Ghanem M; Alderazi Y; Kim Y; Poitevint C; Mir O Cureus; 2023 Oct; 15(10):e46889. PubMed ID: 37859677 [TBL] [Abstract][Full Text] [Related]
2. Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration. Warach SJ; Ranta A; Kim J; Song SS; Wallace A; Beharry J; Gibson D; Cadilhac DA; Bladin CF; Kleinig TJ; Harvey J; Palanikumar L; Doss VT; Marescalco R; Fink JN; Tyson A; Schlick KH; Noh L; Wilson D; Figueroa S; Pech MA; Paletz LB; Lewis MK; Castro M; Sahlein DH; Lafranchise EF; Sandall J; Asif KS; Geraghty SR; Cullis PA; Malisch T; Neill TA; LaMonte MP; Campbell BCV; Wu TY JAMA Neurol; 2023 Jul; 80(7):732-738. PubMed ID: 37252708 [TBL] [Abstract][Full Text] [Related]
3. Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke. Tsivgoulis G; Katsanos AH; Christogiannis C; Faouzi B; Mavridis D; Dixit AK; Palaiodimou L; Khurana D; Petruzzellis M; Psychogios K; Macleod MJ; Ahmed N Ann Neurol; 2022 Sep; 92(3):349-357. PubMed ID: 35713213 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials. Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M; Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822 [TBL] [Abstract][Full Text] [Related]
5. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety outcomes of Tenecteplase versus Alteplase for thrombolysis of acute ischemic stroke: A meta-analysis of 9 randomized controlled trials. Wang Y; Cai X; Fang Q; Zhu J J Neurol Sci; 2024 Mar; 458():122912. PubMed ID: 38325064 [TBL] [Abstract][Full Text] [Related]
7. Tenecteplase Versus Alteplase for Acute Stroke: Mortality and Bleeding Complications. Murphy LR; Hill TP; Paul K; Talbott M; Golovko G; Shaltoni H; Jehle D Ann Emerg Med; 2023 Dec; 82(6):720-728. PubMed ID: 37178103 [TBL] [Abstract][Full Text] [Related]
9. Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial. Singh N; Almekhlafi MA; Bala F; Ademola A; Coutts SB; Deschaintre Y; Khosravani H; Buck B; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar JJ; Ghrooda E; Poppe AY; Williams H; Field TS; Manosalva A; Siddiqui MM; Zafar A; Imoukhoude O; Hunter G; Shamy M; Demchuk AM; Claggett BL; Hill MD; Sajobi TT; Swartz RH; Menon BK Stroke; 2023 Nov; 54(11):2766-2775. PubMed ID: 37800372 [TBL] [Abstract][Full Text] [Related]
10. Tenecteplase versus alteplase for patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Zhang X; Wan TF; Chen J; Liu L Aging (Albany NY); 2023 Dec; 15(24):14889-14899. PubMed ID: 38149983 [TBL] [Abstract][Full Text] [Related]
11. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250 [TBL] [Abstract][Full Text] [Related]
12. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Wang Y; Li S; Pan Y; Li H; Parsons MW; Campbell BCV; Schwamm LH; Fisher M; Che F; Dai H; Li D; Li R; Wang J; Wang Y; Zhao X; Li Z; Zheng H; Xiong Y; Meng X; Lancet; 2023 Feb; 401(10377):645-654. PubMed ID: 36774935 [TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials. Yogendrakumar V; Churilov L; Mitchell PJ; Kleinig TJ; Yassi N; Thijs V; Wu T; Shah D; Bailey P; Dewey HM; Choi PMC; Ma A; Wijeratne T; Garcia-Esperon C; Cloud G; Chandra RV; Cordato DJ; Yan B; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM; Campbell BCV; Neurology; 2023 May; 100(18):e1900-e1911. PubMed ID: 36878701 [TBL] [Abstract][Full Text] [Related]